Comparison between serum hsCRP and LDL cholesterol for search of a better predictor for ischemic heart disease

Indian Journal of Clinical Biochemistry

Volumn 26, Issue 2, 2011, Pages 210-213

  Datta, Subinay ^a   Iqbal, Zahidul ^a   Prasad, K R ^a  

^a Katihar Medical College   (India)

Author keywords

Atherosclerosis; hsCRP; LDL cholesterol; Myocardial infarction

Indexed keywords

EID: 84897957589     PISSN: 09701915     EISSN: 09740422     Source Type: Journal    
DOI: 10.1007/s12291-010-0100-4     Document Type: Article

References (36)

1. Global Strategy on Diet, Physical Activity & Health. http://www.who.int/dietphysicalactivity/publications/facts/cvd/en.
2. Kumar V, Abbas AK, Fausto N. Robbins and Cotran pathologic basis of disease. 3rd ed. Philadelphia: W.B. Saunder Company; 2007.
3. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med. 2002;8:1257-62. (Pubitemid 35373557)
4. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-74. (Pubitemid 36019640)
5. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
6. Uotila M, Ruoslanti E, Enguall E. Two-site sandwich enzyme immunoassay with monoclonal antibodies to human alphafetoprotein. J Immunol Methods. 1981;42:11-5. (Pubitemid 11155944)
7. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. Centers for disease control and prevention, American Heart Association: markers of inflammation and cardiovascular diseases application to clinical and public health practice: a statement for health care professionals from the Centre for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511. (Pubitemid 36158056)
8. McPherson RA, Pincus MR. Henry's clinical diagnosis and management by laboratory methods. 21st ed. New Delhi: Elsevier; 2007. p. 209.
9. Cuchel M, Rader DJ. Low density lipoprotein receptors and familial hypercholesterolemia in Clinical Studies in Clinical Biochemistry. 3rd ed. New York: Oxford University Press; 2007. p. 152-9.
10. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbeshatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47. (Pubitemid 28213628)
11. Lipid research clinics programme. The lipid research clinics coronary primary prevention trial results I; reduction in the incidence of coronary heart diseases. JAMA. 1984;251:351-64.
12. Castelli WP. Cholesterol and lipids in the risk of coronary artery diseases-the Framingham heart study. Can J Cardiol. 1988;4(suppl):5A-10A.
13. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low density lipoprotein subclass patterns and risk of myocvardial infarction. JAMA. 1988;260:1917-21.
14. Lanarche B, Tchernof A, Moorjani S, Cantin B, Dagenais G, Lupien P, Despres JP. Small density low density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Québec cardiovascular study. Circulation. 1997;95:69-75. (Pubitemid 27029945)
15. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 1982;23:97-104. (Pubitemid 12112617)
16. Ridker PM. The pathogenesis of atherosclerosis and acute thrombosis relevance to strategies of cardiovascular disease prevention. In: Manson JE, Ridker PM, Gaziano JM, Hennekens CH, editors. Prevention of myocardial infarction. New York: Oxford University Press; 1996. p. 32-54.
17. Ridker PM. Inflammation, infection and cardiovascular risk: how good is the clinical evidence. Circulation. 1998;97:1671-4. (Pubitemid 28211414)
18. Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser SL, Larry Jameson J, Loscalzo J. Harrison's principles of internal medicine. 17th ed. New York: Mc Graw Hill Companies; 2008. p. 1502.
19. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165-8.
20. Yeh ETH, Anderson HV, Pasceri V, Willerson JT. C-reactive protein: linking inflammation to cardiovascular complications. Circulation. 2001;104:974-5. (Pubitemid 32803869)
21. Willerson JT. Systemic and local inflammation in patients with unstable atherosclerotic plaques. Prog Cardiovasc Dis. 2002;44:469-78. (Pubitemid 34680194)
22. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer M, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88-92. (Pubitemid 28026634)
23. Nakagomi A, Feedman SB, Geczy CL. Interferon and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein. Relationship with age, sex, and hormone replacement treatment. Circulation. 2000;101:1785-91. (Pubitemid 30213099)
24. Verma S, Wang C-H, Li S-H, Dumont AS, Fedak PWM, Badiwala MV, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913-9. (Pubitemid 34925323)
25. Braunwald E. Sahttuck lecture-cardiovascular medicine at the turn of the millennium: triumph, concerns and opportunities. N Engl J Med. 1997;337:1360-9.
26. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89(9):763-71. (Pubitemid 34633846)
27. Blake GJ, Ridker PM. Inflammatory biomarkers and cardio-vascular risk prediction. J Intern Med. 2002;252(4):283-94. (Pubitemid 35253696)
28. D'Aiuto F, Casas JP, Shah T, Humphrics SE, Hingorani AD, Tonetti MS. C-reactive protein (+1444C>T) polymorphism influences CRP response following a moderate inflammatory stimulus. Atherosclerosis. 2005;179(2):413-7. (Pubitemid 40364638)
29. Sharma SB, Garg S, Veerwal A, Dwivedi S. hs-CRP and oxidative stress in young CAD patients. Ind J Clin Biochem. 2008;23(4):334-6.
30. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, D'Agostino RB, Franzblau C, Wilson PW. Plasma concentration of C-reactive protein and risk of ischaemic stroke and transient ischemic attack: the Framingham study. Stroke. 2001;32(11):2575-9. (Pubitemid 33055308)
31. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109:II2-II10. http://circ.ahajournals.org. (Pubitemid 38724149)
32. The emerging risk factors collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke and mortality: an individual participant meta-analysis. Lancet. 2010;375:132-40.
33. Levinson SS. Brief review and clinical examination of the use of hsCRP for cardiac risk assessment with the conclusion that it is premature to use this test. Clin Chim Acta. 2005;356(1-2):1-8. (Pubitemid 40779882)
34. Shalia KK, Shah VK, Mashru MR, Soneji SL, Vasvani JB, Payannavar SS, Walvalkar AP, Mokal RA, Mithbawkar SM, Kundalkar KV, Abraham A, Thakur PK. Circulating thrombotic and haemostatic components in patients with coronary artery disease. Ind J Clin Biochem. 2010;25(1):20-8.
35. Ridker PM, Darielson E, Fonacca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koehig W, Libby P, Lorenzatti AJ, Mac Fadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. On behalves of JUPITER trial study group. Rosuvastatin to prevent vascular events in men and women with elevated CRP. N Engl J Med. 2008;359(21):2195-207.
36. Ridker PM, Darielson E, Fonacca FA, Genest J, Jr Gotto AM, Kastelein JJ, Koehig W, Libby P, Lorenzatti AJ, Mac Fadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, On behalves of JUPITER trial study group. Reduction in CRP and LDL-C and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175-82.